RGD_PLGA Nanoparticles with Docetaxel: A Route for Improving Drug Efficiency and Reducing Toxicity in Breast Cancer Treatment

Simple Summary Breast cancer is the most prevalent cancer in women and the leading cause of cancer-associated deaths. Although several therapeutic approaches are available, systemic chemotherapy remains the primary choice, especially for the treatment of advanced breast cancers. Unfortunately, systemic chemotherapy causes numerous side effects and damage to distal organs and requires high doses of drugs to achieve a therapeutic concentration in the tumor region. The use of nanosystems for drug delivery is a promising strategy to overcome these drawbacks. In this study, we developed Poly (lactic-co-glycolic acid) nanoparticles (PLGA-NPs) containing the chemotherapeutic drug Docetaxel, functionalized with a cyclic RGD tripeptide to allow the active targeting of alpha(v)beta(3) integrins, which are overexpressed in breast cancer. We demonstrated that PLGAs effectively deliver the drug to breast cancer cells in preclinical models, and are more effective than free Docetaxel in hampering tumor progression, while reducing side effects. Breast cancer is the leading cause of cancer-related death in women. Although many therapeutic approaches are available, systemic chemotherapy remains the primary choice, especially for triple-negative and advanced breast cancers. Unfortunately, systemic chemotherapy causes serious side effects and requires high doses to achieve an effective concentration in the tumor. Thus, the use of nanosystems for drug delivery may overcome these limitations. Herein, we formulated Poly (lactic-co-glycolic acid) nanoparticles (PLGA-NPs) containing Docetaxel, a fluorescent probe, and a magnetic resonance imaging (MRI) probe. The cyclic RGD tripeptide was linked to the PLGA surface to actively target alpha(v)beta(3) integrins, which are overexpressed in breast cancer. PLGA-NPs were characterized using dynamic light scattering, fast field-cycling H-1-relaxometry, and H-1-nuclear magnetic resonance. Their therapeutic effects were assessed both in vitro in triple-negative and HER2+ breast cancer cells, and in vivo in murine models. In vivo MRI and inductively coupled plasma mass spectrometry of excised tumors revealed a stronger accumulation of PLGA-NPs in the RGD_PLGA group. Targeted PLGAs have improved therapeutic efficacy and strongly reduced cardiac side effects compared to free Docetaxel. In conclusion, RGD-PLGA is a promising system for breast cancer treatment, with positive outcome in terms of therapeutic efficiency and reduction in side effects.